Amplification of the urokinase-type plasminogen activator receptor (uPAR) gene in ductal pancreatic carcinomas identifies a clinically high-risk group

American Journal of Pathology

Volumn 174, Issue 6, 2009, Pages 2246-2253

  Hildenbrand, Ralf ^a,b,c   Niedergethmann, Marco ^b   Marx, Alexander ^b   Belharazem, Djeda ^b   Allgayer, Heike ^b   Schleger, Christiane ^b   Ströbel, Philipp ^b  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Institut fur Pathologie   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

UROKINASE; UROKINASE RECEPTOR;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER RISK; CLINICAL ARTICLE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PANCREAS CARCINOMA; PANCREAS DUCT; PRECANCER; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 67049164972     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.080785     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96
2. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108
3. Niedergethmann M, Alves F, Neff JK, Heidrich B, Aramin N, Li L, Pilarsky C, Grutzmann R, Allgayer H, Post S, Gretz N: Gene expression profiling of liver metastases and tumour invasion in pancreatic cancer using an orthotopic SCID mouse model. Br J Cancer 2007, 97:1432-1440 (Pubitemid 350114784)
4. Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH: Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev 2008, 34:122-136
5. Duffy MJ, McGowan PM, Gallagher WM: Cancer invasion and metastasis: changing views. J Pathol 2008, 214:283-293 (Pubitemid 351212383)
6. Hildenbrand R, Gandhari M, Stroebel P, Marx A, Allgayer H, Arens N: The urokinase-system - role of cell proliferation and apoptosis. Histol Histopathol 2008, 23:227-236
7. Danø K, Behrendt N, Hoyer-Hansen G, Johnsen M, Lund LR, Ploug M, Romer J: Plasminogen activation and cancer. Thromb Haemost 2005, 93:676-681 (Pubitemid 40485402)
8. Schmitt M, Harbeck N, Thomssen C, Wilhelm O, Magdolen V, Reuning U, Ulm K, Hofler H, Janicke F, Graeff H: Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost 1997, 78:285-296 (Pubitemid 27289256)
9. Hildenbrand R, Wolf G, Bohme B, Bleyl U, Steinborn A: Urokinase plasminogen activator receptor (CD87) expression of tumor-associated macrophages in ductal carcinoma in situ, breast cancer, and resident macrophages of normal breast tissue. J Leukoc Biol 1999, 66:40-49 (Pubitemid 29321368)
10. Hildenbrand R, Arens N: Protein and mRNA expression of uPAR and PAI-1 in myoepithelial cells of early breast cancer lesions and normal breast tissue. Br J Cancer 2004, 91:564-571 (Pubitemid 39093580)
11. Gandhari M, Arens N, Majety M, Dorn-Beineke A, Hildenbrand R: Urokinase-type plasminogen activator induces proliferation in breast cancer cells. Int J Oncol 2006, 28:1463-1470
12. Aguirre-Ghiso JA, Liu D, Mignatti A, Kovalski K, Ossowski L: Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell 2001, 12:863-879 (Pubitemid 33051984)
13. Aguirre Ghiso JA, Kovalski K, Ossowski L: Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol 1999, 147:89-104 (Pubitemid 30211799)
14. Tang H, Kerins DM, Hao Q, Inagami T, Vaughan DE: The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells. J Biol Chem 1998, 273:18268-18272 (Pubitemid 28334749)
15. Ma Z, Webb DJ, Jo M, Gonias SL: Endogenously produced urokinase- type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB- 231 breast cancer cells. J Cell Sci 2001, 114:3387-3396 (Pubitemid 33009262)
16. Liehr T, Grehl H, Rautenstrauss B: FISH analysis of interphase nuclei extracted from paraffin-embedded tissue. Trends Genet 1995, 11:377-378
17. Schleger C, Verbeke C, Hildenbrand R, Zentgraf H, Bleyl U: c-MYC activation in primary and metastatic ductal adenocarcinoma of the pancreas: incidence, mechanisms, and clinical significance. Mod Pathol 2002, 15:462-469 (Pubitemid 34326956)
18. Hildenbrand R, Leitz M, Magdolen V, Luther T, Albrecht S, Graeff H, Stutte HJ, Bleyl U, Schmitt M: Validation of immunolocalization of the urokinase receptor expression in ductal carcinoma in situ of the breast: comparison with detection by non-isotopic in-situ hybridization. Histopathology 2000, 36:499-504 (Pubitemid 30348774)
19. Magdolen V, Rettenberger P, Lopens A, Oi H, Lottspeich F, Kellermann J, Creutzburg S, Goretzki L, Weidle UH, Wilhelm O, Schmitt M, Graeff H: Expression of the human urokinase-type plasminogen activator receptor in E. coli and Chinese hamster ovary cells: purification of the recombinant proteins and generation of polyclonal antibodies in chicken. Electrophoresis 1995, 16:813-816
20. Hildenbrand R, Glienke W, Magdolen V, Graeff H, Stutte HJ, Schmitt M: Urokinase receptor localization in breast cancer and benign lesions assessed by in situ hybridization and immunohistochemistry. Histochem Cell Biol 1998, 110:27-32 (Pubitemid 28293870)
21. Hildenbrand R, Dilger I, Horlin A, Stutte HJ: Urokinase and macrophages in tumour angiogenesis. Br J Cancer 1995, 72:818-823
22. Friess H, Cantero D, Graber H, Tang WH, Guo X, Kashiwagi M, Zimmermann A, Gold L, Korc M, Buchler MW: Enhanced urokinase plasminogen activation in chronic pancreatitis suggests a role in its pathogenesis. Gastroenterology 1997, 113:904-913 (Pubitemid 27381151)
23. Mazar AP: Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy. Clin Cancer Res 2008, 14:5649-5655
24. Cantero D, Friess H, Deflorin J, Zimmermann A, Brundler MA, Riesle E, Korc M, Buchler MW: Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer 1997, 75:388-395 (Pubitemid 27051054)
25. Schleger C, Arens N, Zentgraf H, Bleyl U, Verbeke C: Identification of frequent chromosomal aberrations in ductal adenocarcinoma of the pancreas by comparative genomic hybridization (CGH). J Pathol 2000, 191:27-32 (Pubitemid 30235645)
26. Harada T, Baril P, Gangeswaran R, Kelly G, Chelala C, Bhakta V, Caulee K, Mahon PC, Lemoine NR: Identification of genetic alterations in pancreatic cancer by the combined use of tissue microdissection and array-based comparative genomic hybridisation. Br J Cancer 2007, 96:373-382 (Pubitemid 46160645)
27. Furukawa T, Sunamura M, Horii A: Molecular mechanisms of pancreatic carcinogenesis. Cancer Sci 2006, 97:1-7 (Pubitemid 43257020)
28. Wiechmann L, Kuerer HM: The molecular journey from ductal carcinoma in situ to invasive breast cancer. Cancer 2008, 112:2130-2142 (Pubitemid 351628621)
29. O'Connell P, Pekkel V, Fuqua SA, Osborne CK, Clark GM, Allred DC: Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst 1998, 90:697-703 (Pubitemid 28222144)
30. Hwang ES, DeVries S, Chew KL, Moore II DH, Kerlikowske K, Thor A, Ljung BM, Waldman FM: Patterns of chromosomal alterations in breast ductal carcinoma in situ. Clin Cancer Res 2004, 10:5160-5167 (Pubitemid 39099791)
31. Stratton MR, Collins N, Lakhani SR, Sloane JP: Loss of heterozygosity in ductal carcinoma in situ of the breast. J Pathol 1995, 175:195-201
32. Duggan C, Maguire T, McDermott E, O'Higgins N, Fennelly JJ, Duffy MJ: Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int J Cancer 1995, 61:597-600